Lipocine (NASDAQ:LPCN – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday.
Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price on the stock.
Check Out Our Latest Analysis on LPCN
Lipocine Trading Down 0.5 %
Lipocine (NASDAQ:LPCN – Get Free Report) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) EPS for the quarter. The business had revenue of $0.09 million for the quarter. Research analysts expect that Lipocine will post -0.92 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Lipocine
An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in shares of Lipocine Inc. (NASDAQ:LPCN – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent quarter. Hedge funds and other institutional investors own 9.11% of the company’s stock.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Read More
- Five stocks we like better than Lipocine
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- How to Invest in Blue Chip Stocks
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.